Literature DB >> 6541534

Two direct (nonchromatographic) assays for 25-hydroxyvitamin D.

R Bouillon, E Van Herck, I Jans, B K Tan, H Van Baelen, P De Moor.   

Abstract

We describe direct, nonchromatographic assays for 25-hydroxyvitamin D3 in which we use either rat vitamin D-binding protein or rabbit antibodies to 25-hydroxyvitamin D3-3-hemisuccinate-bovine serum albumin as binding protein. Nonspecific interferences in serum could be eliminated by an appropriate extraction method or in obtaining data for the calibration curve, by using vitamin D-free human serum. The latter is prepared by affinity chromatography with use of immobilized antibodies against human vitamin D-binding protein. Values obtained by the direct assays and those obtained by two different chromatographic methods correlated well (r greater than 0.95). The direct competitive protein-binding assay overestimated the true 25-hydroxyvitamin D3 concentration by about 20%, but this percentage was constant from 5 to 600 micrograms/L. Overestimation by the direct radioimmunoassay was less than 10%. These two direct assays for 25-hydroxyvitamin D3 allow reliable, rapid, and simple screening for vitamin D deficiency or excess.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6541534

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  13 in total

1.  Inaccuracies in relating 25-hydroxyvitamin D to ischemic heart disease.

Authors:  Reinhold Vieth; D Sudhaker Rao
Journal:  Eur J Epidemiol       Date:  2003       Impact factor: 8.082

2.  Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism.

Authors:  Pieter Evenepoel; Björn Meijers; Liesbeth Viaene; Bert Bammens; Kathleen Claes; Dirk Kuypers; Dirk Vanderschueren; Yves Vanrenterghem
Journal:  Clin J Am Soc Nephrol       Date:  2010-05-06       Impact factor: 8.237

3.  ACP Broadsheet no 144: July 1994. The investigation of hypercalcaemia. Association of Clinical Pathologists.

Authors:  P L Selby; P H Adams
Journal:  J Clin Pathol       Date:  1994-07       Impact factor: 3.411

4.  Measuring total blood calcium displays a low sensitivity for the diagnosis of hypercalcemia in incident renal transplant recipients.

Authors:  Pieter Evenepoel; Bert Bammens; Kathleen Claes; Dirk Kuypers; Björn K I Meijers; Yves Vanrenterghem
Journal:  Clin J Am Soc Nephrol       Date:  2010-09-09       Impact factor: 8.237

Review 5.  Assessment and interpretation of circulating 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in the clinical environment.

Authors:  Bruce W Hollis
Journal:  Endocrinol Metab Clin North Am       Date:  2010-06       Impact factor: 4.741

6.  Fibroblast growth factor-23 and parathyroid hormone are associated with post-transplant bone mineral density loss.

Authors:  Nada Kanaan; Kathleen Claes; Jean-Pierre Devogelaer; Dirk Vanderschueren; Genevieve Depresseux; Eric Goffin; Pieter Evenepoel
Journal:  Clin J Am Soc Nephrol       Date:  2010-07-15       Impact factor: 8.237

7.  Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation.

Authors:  Pieter Evenepoel; Bjorn K I Meijers; Hylke de Jonge; Maarten Naesens; Bert Bammens; Kathleen Claes; Dirk Kuypers; Yves Vanrenterghem
Journal:  Clin J Am Soc Nephrol       Date:  2008-10-15       Impact factor: 8.237

8.  Calcium metabolism in the early posttransplantation period.

Authors:  Pieter Evenepoel; Barbara Van Den Bergh; Maarten Naesens; Hylke De Jonge; Bert Bammens; Kathleen Claes; Dirk Kuypers; Yves Vanrenterghem
Journal:  Clin J Am Soc Nephrol       Date:  2009-03-04       Impact factor: 8.237

Review 9.  Vitamin D Assays.

Authors:  Daniel D Bikle
Journal:  Front Horm Res       Date:  2018-03-29       Impact factor: 2.606

10.  Natural History of Bone Disease following Kidney Transplantation.

Authors:  Hanne Skou Jørgensen; Geert Behets; Bert Bammens; Kathleen Claes; Bjorn Meijers; Maarten Naesens; Ben Sprangers; Dirk R J Kuypers; Etienne Cavalier; Patrick D'Haese; Pieter Evenepoel
Journal:  J Am Soc Nephrol       Date:  2022-01-19       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.